SCT200 is a fully humanized IgG1 monoclonal antibody targeting EGFR, with a Kd value of 0.08 nM. It can eliminate tumor cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through its Fc fragment. SCT200 is utilized in research on refractory RAS and BRAF wild-type metastatic colorectal cancer.
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted
